Montelukast sodium : administration to children to control intermittent asthma

Loading...
Thumbnail Image

Date

Authors

Gravett, Cornelia M.
Tintinger, Gregory Ronald
Theron, Annette J.
Anderson, Ronald
Feldman, Charles
Green, Robin J.

Journal Title

Journal ISSN

Volume Title

Publisher

Libertas Academica

Abstract

The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the chemotherapy of exercise-induced asthma. It has also been used as add-on therapy in patients whose asthma is poorly controlled with inhaled corticosteroid monotherapy, or with the combination of a long-acting β(2)-agonist and an inhaled corticosteroid. Recently, however, montelukast has been reported to possess secondary anti-inflammatory properties, apparently unrelated to conventional antagonism of cysteinyl leukotriene receptors. These novel activities enable montelukast to target eosinophils, monocytes, and, in particular, the corticosteroid-insensitive neutrophil, suggesting that this agent may have a broader spectrum of anti-inflammatory activities than originally thought. If so, montelukast is potentially useful in the chemotherapy of intermittent asthma because most exacerbations of this condition involve respiratory virus infection-triggered inflammatory mechanisms which, to a large extent, involve airway epithelial cell/neutrophil interactions. The primary objective of this review is to evaluate the role of montelukast in the treatment of intermittent asthma in children.

Description

Keywords

Airway epithelial cells, Corticosteroids, Inflammation, Neutrophils, Respiratory viruses, Virus-induced wheeze, Montelukast sodium

Sustainable Development Goals

Citation

Gravett, CM, Tintinger, GR, Theron, AJ, Anderson, R, Feldman, C & Green, R 2010, 'Montelukast sodium : administration to children to control intermittent asthma', Clinical Medicine Reviews in Therapeutics, vol. 2, pp. 1-10. [http://www.la-press.com/clinical-medicine-reviews-in-therapeutics-journal-j166]